{
    "clinical_study": {
        "@rank": "62065", 
        "arm_group": [
            {
                "arm_group_label": "Limaprost & Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Limaprost 5\u338d tablet and a capsule of Pegabalin-Placebo thrice a day for 8 weeks."
            }, 
            {
                "arm_group_label": "Pregabalin & Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Pregabalin 75mg capsule and a tablet of Limaprost-Placebo thrice a day for 8 weeks."
            }, 
            {
                "arm_group_label": "Limaprost+Pregabalin", 
                "arm_group_type": "Active Comparator", 
                "description": "Limaprost 5\u338d tablet and Pregabalin 75mg capsule thrice a day for 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is a comparative study of Opast tablet and Rikalin capsule 75mg and Rikalin\n      capsule 75mg in combination with Opast tablet to evaluate improvement effectiveness of Opast\n      tablet on subjective symptoms and neurologic claudication in patients with lumbar spinal\n      stenosis."
        }, 
        "brief_title": "A Study to Evaluate Efficacy of \u300eOpast Tablet\u300ffor Neurologic Claudication in Patients With Lumbar Spinal Stenosis", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Neurologic Claudication in Patients With Lumbar Spinal Stenosis", 
        "condition_browse": {
            "mesh_term": [
                "Constriction, Pathologic", 
                "Spinal Stenosis", 
                "Intermittent Claudication"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects who provided written consents voluntarily after receiving a sufficient explanation\n      about this trial will be assigned to one of groups(study group; limaprost, comparative group\n      1; pregabalin, comparative group 2; limaprost+ pregabalin) by randomization at the rate of\n      1:1:1.\n\n      Subjects will take assigned investigational drugs thrice a day for eight weeks by\n      double-blind and double-dummy methods, and they will visit the site two times at intervals\n      of four weeks.\n\n      At each site visit point, the improvement effectiveness will be comparatively evaluated by\n      evaluation of following endpoints;\n\n      Efficacy endpoints: ICD(initial claudication distance) at treadmill test (speed:3km/hr,\n      grade:0%), VAS in pain on lower extremities, EQ-5D and ODI Safety endpoints: Vital signs,\n      hematology/blood chemistry tests and adverse events, etc."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is fully understand the clinical trial and obtained informed consent.\n\n          -  Age 20-75years.\n\n          -  Patients with a confirmed diagnosis of waist of spinal canal stenosis.\n\n          -  Limb pain caused by waist of spinal canal stenosis index of VAS 3 or more patients.\n\n          -  Subject who has numbness symptom on lower extremity(ies) and intermittent\n             claudication that are due to spinal canal stenosis and fulfills both of    following\n             criteria at the same time\n\n               -  When screening visit, a medical examination by interview had the following\n                  symptoms in subjects ; In daily life walking, when walked by within 20 minutes\n                  on flatland, the subject can feel the symptoms (numbness, pain or tightness on\n                  lower extremity(ies), etc.)\n\n                    -  Subject who experienced numbness, pain, tightness or other similar\n                       symptom(s) on lower extremity within 15 minutes from test start at\n                       baseline(D1) evaluation.\n\n                         -  speed: 3km/hr, grade:0%, posture: should keep their lumbar spinal\n                            extended\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women of childbearing potential not employing          adequate\n             contraception.\n\n          -  Patients who have the hereditary problem of galactose intolerance, Lapp lactase\n             deficiency or grape sugar-galactose absorption defect.\n\n          -  Patients with systemic disease affecting the lower limbs.\n\n          -  Patients who have cauda equina syndrome.\n\n          -  Patients with acute osteoporosis compression fracture in lumbar vertebra.\n\n          -  Patients who have gait disturbance of degenerative arthritis by hip joint, knee\n             joint, ankle joint.\n\n          -  At least one month before the start of the study, patients use of steroid drug except\n             lumbar dura mater.\n\n          -  6 month before the start of the study, patients with ischaemic disease in     blood\n             vessel, lung or the coronary artery,  varicose artery.\n\n          -  Patients with lumbar necrosis in head of femur avascular necrosis, necrotic foot\n             ulcer.\n\n          -  Patients surgery by lumbar fusion and lumbar decompression.\n\n          -  Patients with renal disease or need to hemodialysis.\n\n               -  serum creatinine > 2xUNL\n\n          -  3 month before the start of the study, patients participated in another clinical\n             research.\n\n          -  Patients with difficult understanding spirit incompetence, lack of will or language\n             barrier.\n\n          -  The investigator judged seriously ill patients need surgery patient."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888536", 
            "org_study_id": "YJ7-401"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Limaprost & Placebo", 
                    "Limaprost+Pregabalin"
                ], 
                "intervention_name": "Limaprost", 
                "intervention_type": "Drug", 
                "other_name": "Opast tablet"
            }, 
            {
                "arm_group_label": [
                    "Pregabalin & Placebo", 
                    "Limaprost+Pregabalin"
                ], 
                "intervention_name": "Pregabalin", 
                "intervention_type": "Drug", 
                "other_name": "Rikalin capsule 75mg"
            }, 
            {
                "arm_group_label": "Limaprost & Placebo", 
                "description": "mimic Pregabalin 75mg capsule", 
                "intervention_name": "Placebo(for Pregabalin)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pregabalin & Placebo", 
                "description": "mimic Limaprost tablet", 
                "intervention_name": "Placebo(for Limaprost)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pregabalin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 26, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Moon Soo Park, M.D.,Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Anyang-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "431-070"
                    }, 
                    "name": "Hallym University Sacred Heart Hospital"
                }, 
                "investigator": {
                    "last_name": "Moon Soo Park, M.D.,Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ye Soo Park, M.D.,Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Guri-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "471-701"
                    }, 
                    "name": "Hanyang University Guri Hospital"
                }, 
                "investigator": {
                    "last_name": "Ye Soo Park, M.D.,Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ho Joong Kim, M.D.,Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seongnam-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "463-707"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }, 
                "investigator": {
                    "last_name": "Ho Joong Kim, M.D.,Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Suk Kyung Soo, M.D.,Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "130-872"
                    }, 
                    "name": "KyungHee University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Suk Kyung Soo, M.D.,Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jin Hyok Kim, M.D.,Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "139-707"
                    }, 
                    "name": "Inje University Sanggye Paik Hospital"
                }, 
                "investigator": {
                    "last_name": "Jin Hyok Kim, M.D.,Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jae Hyup Kim, M.D.,Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "156-707"
                    }, 
                    "name": "SMG-SNU Boramae Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jae Hyup Lee, M.D.,Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "shmoon@yuhs.ac", 
                    "last_name": "Seong-Hwan Moon, M.D.,Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-752"
                    }, 
                    "name": "Yonsei University Health System, Severance Hospital"
                }, 
                "investigator": {
                    "last_name": "Seong Hwan Moon, M.D.,Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Comparative, Multi-Center, Phase \u2163 Clinical Trial to Evaluate Efficacy of \u300eOpast Tablet\u300ffor Neurologic Claudication in Patients With Lumbar Spinal Stenosis", 
        "overall_contact": {
            "email": "shmoon@yuhs.ac", 
            "last_name": "Seong-Hwan Moon, M.D.,Ph.D", 
            "phone": "82-2-2228-2188"
        }, 
        "overall_official": [
            {
                "affiliation": "Yonsei University College of Medicine Severance Hospital", 
                "last_name": "Seong-Hwan Moon, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University", 
                "last_name": "Jin Hyok Kim, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "SMG-SNU Boramae Medical Center", 
                "last_name": "Jae Hyup Lee, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyunghee University Medical Center", 
                "last_name": "Suk Kyung Soo, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Bundang Hospital", 
                "last_name": "Ho Joong Kim, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hanyang University", 
                "last_name": "Ye Soo Park, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hallym University Medical Center", 
                "last_name": "Moon Soo Park, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Institutional Review Board", 
                "Korea: Ministry of Food and Drug Safety"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": ": Improvement of ICD at 8 weeks after first administration compared to                baseline, between study group(limaprost) and comparative group1(pregabalin)", 
            "measure": "Initial Claudication Distance(ICD) on treadmill test", 
            "safety_issue": "No", 
            "time_frame": "up to 8 weeks after first administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888536"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Improvement of ICD at 4 weeks after first administration compared to             baseline, between study group(limaprost) and comparative group1(pregabalin)\nImprovement of ICD at 4, 8 weeks after first administration compared to          baseline, between study group(limaprost) and comparative group 2(limaprost+       pregabalin)", 
                "measure": "Initial Claudication Distance(ICD) on treadmill test", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks after first administration"
            }, 
            {
                "description": "Change in VAS at 4, 8 weeks after first administration compared to               baseline, between study group(limaprost) and comparative group1(pregabalin)\nChange in VAS at 4, 8 weeks after first administration compared to               baseline, between study group(limaprost) and comparative group 2(limaprost+       pregabalin)", 
                "measure": "lower extremity pain score measured by Visual Analog Scale(VAS) 10cm", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks after first administration"
            }, 
            {
                "description": "Change in EQ-5D at 4, 8 weeks after first administration compared to            baseline, between study group(limaprost) and comparative group1(pregabalin)\nChange in EQ-5D at 4, 8 weeks after first administration compared to            baseline, between study group(limaprost) and comparative group 2(limaprost+       pregabalin)", 
                "measure": "Mean ratio of change in score of EuroQuol 5D (EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks after first administration"
            }, 
            {
                "description": "Change in ODI at 4, 8 weeks after first administration compared to               baseline, between study group(limaprost) and comparative group1(pregabalin)\nChange in ODI at 4, 8 weeks after first administration compared to               baseline, between study group(limaprost) and comparative group 2(limaprost+       pregabalin)", 
                "measure": "Mean ratio of change in score of Oswestry Disability Index(ODI)", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks after first administration"
            }
        ], 
        "source": "Yungjin Pharm. Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yungjin Pharm. Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}